Vertex Pharmaceuticals vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vertex Pharmaceuticals (VRTX) reported $10.7B revenue in FY2024, up 12% YoY. Global leader in cystic fibrosis treatment. Near-monopoly on CF drugs. HQ: Boston, MA. Market cap ~$110B.
About
Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Also Compare
Vertex Pharmaceuticals vs
Regeneron Pharmaceuticals vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.